Cardialysis Named “Top Cardiovascular Research Organization in Europe 2026” by Life Sciences Review Europe.

Cardialysis, a Rotterdam-based specialized clinical research organization (CRO) and independent cardiovascular core laboratory supporting global studies in interventional cardiology and structural heart therapies, announced that it has been named “Top Cardiovascular Research Organization in Europe 2026” by Life Sciences Review Europe.

This recognition reflects more than four decades of work in cardiovascular clinical research, including recent studies presented by the company at ACC26 in New Orleans.

Cardialysis contributed to three late-breaking clinical trials simultaneously published in the New England Journal of Medicine — FAST III, OPTIMAL, and IVUS-CHIP — through its integrated CRO and core laboratory model.

From programs such as SYNTAX and MASTER DAPT to support for more than 400 global trials, Cardialysis continues to advance cardiovascular research across interventional cardiology and structural heart therapies.

[…]

“We are a true one-stop shop research partner for sponsors that helps them deliver high-quality evidence that advances innovative cardiovascular therapies with confidence and efficiency,” said CEO and Medical Director Dr. Ernest Spitzer.

Read the full interview with Cardialysis on the website of Life Sciences Review Europe.